IRIS
PATRIGNANI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.612
EU - Europa 10.111
AS - Asia 9.786
SA - Sud America 1.209
Continente sconosciuto - Info sul continente non disponibili 918
AF - Africa 152
OC - Oceania 15
Totale 37.803
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.313
SG - Singapore 3.606
CN - Cina 3.040
UA - Ucraina 1.828
IE - Irlanda 1.433
GB - Regno Unito 1.321
TR - Turchia 1.253
RU - Federazione Russa 1.229
IT - Italia 1.113
BR - Brasile 985
SE - Svezia 906
VN - Vietnam 830
FR - Francia 829
DE - Germania 634
FI - Finlandia 378
IN - India 315
BD - Bangladesh 162
PL - Polonia 157
HK - Hong Kong 137
CA - Canada 136
AR - Argentina 88
MX - Messico 86
ES - Italia 60
ZA - Sudafrica 59
KR - Corea 58
JP - Giappone 54
IQ - Iraq 53
BE - Belgio 47
CZ - Repubblica Ceca 47
SA - Arabia Saudita 41
NL - Olanda 38
ID - Indonesia 34
EC - Ecuador 32
CO - Colombia 31
PK - Pakistan 26
UZ - Uzbekistan 23
JM - Giamaica 22
AT - Austria 21
EU - Europa 21
VE - Venezuela 21
IL - Israele 19
MA - Marocco 19
AE - Emirati Arabi Uniti 18
LT - Lituania 18
IR - Iran 16
PH - Filippine 16
CL - Cile 15
DZ - Algeria 14
PY - Paraguay 14
EG - Egitto 13
AU - Australia 12
KE - Kenya 12
MY - Malesia 12
PE - Perù 11
HN - Honduras 10
JO - Giordania 10
TN - Tunisia 10
AZ - Azerbaigian 9
OM - Oman 9
CR - Costa Rica 8
RO - Romania 8
TT - Trinidad e Tobago 7
UY - Uruguay 7
BY - Bielorussia 6
GR - Grecia 6
GT - Guatemala 6
KZ - Kazakistan 6
PS - Palestinian Territory 6
PT - Portogallo 6
BB - Barbados 5
LY - Libia 5
NP - Nepal 5
AL - Albania 4
AM - Armenia 4
BO - Bolivia 4
CG - Congo 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
LB - Libano 4
NI - Nicaragua 4
SN - Senegal 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
KW - Kuwait 3
PA - Panama 3
SC - Seychelles 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
DM - Dominica 2
GA - Gabon 2
HR - Croazia 2
HU - Ungheria 2
LK - Sri Lanka 2
MN - Mongolia 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
Totale 36.887
Salva come PNG Salva come JPEG
Città #
Singapore 2.460
Jacksonville 1.968
San Jose 1.858
Chandler 1.728
Dublin 1.423
Southend 1.002
Ashburn 833
Dallas 717
Princeton 706
Council Bluffs 662
Izmir 638
Beijing 626
Dearborn 569
Nanjing 494
Los Angeles 350
Cambridge 324
Wilmington 311
Ho Chi Minh City 283
Tongling 270
Santa Clara 228
Hanoi 201
Nanchang 200
The Dalles 186
Altamura 171
Buffalo 170
Boardman 160
New York 158
Chieti 144
Moscow 139
Shenyang 132
Hong Kong 125
Woodbridge 120
Ann Arbor 114
São Paulo 94
Hebei 93
Kraków 93
Munich 92
Tianjin 84
Grevenbroich 83
Jiaxing 75
Kunming 72
Phoenix 72
Changsha 68
Orem 65
Redondo Beach 61
Columbus 56
Hangzhou 55
Warsaw 55
Rome 53
Hefei 52
Norwalk 52
Seoul 52
Brooklyn 50
Chicago 48
Houston 48
Denver 47
Jinan 46
Washington 46
Montreal 43
Brussels 42
Pescara 42
Tokyo 42
Johannesburg 40
Orange 39
Atlanta 38
Toronto 38
Helsinki 37
Brno 36
Milan 35
Chennai 33
Kocaeli 31
San Francisco 31
Boston 30
Guangzhou 30
Da Nang 29
Mexico City 29
Rio de Janeiro 29
Seattle 29
Shanghai 29
St Louis 29
Ningbo 28
Lanzhou 27
London 27
Haiphong 26
Zhengzhou 26
Augusta 25
Belo Horizonte 25
Poplar 25
Frankfurt am Main 24
Hải Dương 24
Nuremberg 24
San Mateo 24
Mumbai 23
Riyadh 23
Stockholm 23
Manchester 22
Amsterdam 21
Auburn Hills 21
Tashkent 20
Ankara 19
Totale 22.320
Salva come PNG Salva come JPEG
Nome #
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 319
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 274
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 248
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 219
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 191
Antithrombotic Agents and Cancer 184
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 177
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 172
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 167
Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology 167
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 166
Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained 164
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. 162
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 158
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 158
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 158
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 154
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 154
LA CASCATA DELL'ACIDO ARACHIDONICO 152
Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. 152
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 152
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting 149
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 148
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 146
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1 146
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 145
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 143
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 141
Effetto del propranololo e del suo metabolita attivo 4-OH propranololo sui prostanoidi COX-2 derivati e sull’emossigenasi-1 (OH-1) in cellule HUVEC. 141
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 140
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 140
Thromboxane biosynthesis and pulmonary function in cystic fibrosis 139
Rare SNP rs12731181 in the miR-590-3p Target Site of the Prostaglandin F2α Receptor Gene Confers Risk for Essential Hypertension in the Han Chinese Population. 139
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 138
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 137
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. 137
A comparison of low-dose aspirin and dazoxiben as selective inhibitors of thromboxane A2 production in man. 136
[ITALIAN CONSENSUS ON EULAR 2003 RECOMMENDATIONS FOR THE TREATMENT OF KNEE OSTEOARTHRITIS.] 136
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 135
New insights into COX-2 biology and inhibition. 135
ALTERED RENAL AND PLATELET ARACHIDONIC ACID METABOLISM IN CIRRHOSIS. 135
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 135
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 135
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 134
A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. 134
A double-blind randomized study of the anti-platelet effects of low-dose ASA and placebo in patients after myocardial infarction 133
Differential contribution of cycloooxygenase-isozymes to the generation of prostacyclin and prostaglandin E2 by endothelial cells in response to steady laminar shear stress 133
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 133
Therapeutic targeting of dysregulated cellular communication. 133
Oxidative stress and platelet activation in essential hyperytension 132
Determinants of platelet activation in human essential hypertension. 132
Induction of prostacyclin by steady laminar shear stress suppresses Tumor Necrosis Factor-alfa biosyntesis via Heme Oxygenase-1 in human endothelial cells. 131
Clinical pharmacology of selective COX-2 inhibitors. 131
Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. 131
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 130
T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. 130
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 129
Platelet activation in patients with colorectal cancer. 129
Aspirin, platelet inhibition and cancer prevention. 129
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 128
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 128
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. 128
Aspirin and Cancer 128
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 127
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 126
RECOVERY OF THROMBOXANE BIOSYNTHESIS BY ASPIRIN-TREATED PLATELETS IN VITRO: A NOVEL MECHANISM OF ASPIRIN RESISTANCE. 125
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 125
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 124
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 124
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 124
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 124
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 124
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 124
A SELECTIVE THROMBOXANE-SYNTHASE INHIBITOR, ON PLATELET AND RENAL PROSTAGLANDIN ENDOPEROXIDE METABOLISM 123
AMPLIFICATION LOOPS: THROMBOXANE GENERATION. 123
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 123
Gut microbiota, host gene expression, and aging. 123
Risk management profile of etoricoxib: An example of personalized medicine 123
Editorial: Eicosanoids in Cancer 123
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 123
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 122
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 121
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. 121
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 121
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 121
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 121
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 121
Usefulness of enzimatic intermediate markers-example of cox-2 inhibition 120
EFFECTS OF NIMESULIDE ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN MAN. 120
Increased renal thromboxane production in Systemic Lupus Erythematosus. 120
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 120
ANTIINFLAMMATORY COMPOUNDS L-745,337 AND NS-398 ARE SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN HUMAN BLOOD MONOCYTES 120
Clinical pharmacology of novel selective COX-2 inhibitors. 120
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 120
In vitro morphine metabolism by rat microglia. 120
Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications 120
Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk 119
ACTIVATED POLYMORPHONUCLEAR LEUKOCYTES INDUCE A PRO-INFLAMMATORY STATE OF THE ENDOTHELIUM 119
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 119
Role of Platelets in Inflammation and Cancer: Novel Therapeutic Strategies 119
Totale 14.052
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.236 0 0 38 202 122 9 25 103 123 25 192 397
2022/20234.632 374 433 179 589 495 970 291 409 626 55 90 121
2023/20241.827 163 100 131 53 100 456 496 36 7 35 17 233
2024/20254.671 368 638 539 105 104 152 89 383 481 213 545 1.054
2025/202611.348 955 557 1.246 1.366 841 711 1.792 813 1.273 960 590 244
2026/20271.417 435 839 143 0 0 0 0 0 0 0 0 0
Totale 37.803